Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: Rationale and design of the EMPA-HEART trial

Cardiovascular Diabetology

Volumn 16, Issue 1, 2017, Pages

  Natali, Andrea ^a   Nesti, Lorenzo ^a   Fabiani, Iacopo ^a   Calogero, Enrico ^a   Di Bello, Vitantonio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Cardiovascular; Empagliflozin; GLS; Mycardial dysfunction; SGLT2; Speckle tracking

Indexed keywords

BIOLOGICAL MARKER; EMPAGLIFLOZIN; SITAGLIPTIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIOPULMONARY FUNCTION; CARDIOVASCULAR PARAMETERS; CELL DAMAGE; COHORT ANALYSIS; CONTROLLED STUDY; DIASTOLE; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; EXPLORATORY RESEARCH; FEMALE; GLOBAL LONGITUDINAL STRAIN; HEART LEFT ATRIUM; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERPNEA; INFLAMMATION; ITALY; MAJOR CLINICAL STUDY; MALE; MUSCLE CELL; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SPECKLE TRACKING ECHOCARDIOGRAPHY; STUDY DESIGN; SYSTOLE; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TOTAL BODY WATER; VALSALVA MANEUVER; VENOUS OXYGEN TENSION; CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE EXACERBATION; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CARDIOMYOPATHIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; ITALY; MALE; MIDDLE AGED; RESEARCH DESIGN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85030834144     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-017-0615-6     Document Type: Article

References (67)

1. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003;138:10-6.
2. Goyal BR, Mehta AA. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion. Hum Exp Toxicol. 2013;32:571-90.
3. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315-81.
4. Faden G, Faganello G, De Feo S, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013;101:309-16.
5. Cioffi G, Giorda CB, Chinali M, et al. Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. Eur J Prev Cardiol. 2012;19:935-43.
6. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427-34.
7. Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E. SGLT2 and SGLT1 renal expression in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(9):1289-94.
8. Zhou J, Xu J, Huang Z, Wang M. Transporter-mediated tissue targeting of therapeutic molecules in drug discovery. Bioorg Med Chem Lett. 2015;25:993-7.
9. Schwartz SS, Ahmed I. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes. Curr Med Res Opin. 2016;32:907-19.
10. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-28.
11. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
12. Cavender MA, Scirica BM, Raz I, et al. Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c. Am J Med. 2016;129(340):e341-8.
13. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232-42.
14. Hirakawa Y, Arima H, Zoungas S, et al. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care. 2014;37:2359-65.
15. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57.
16. Kosiborod M, Cavender MA, Fu AZ, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249-59.
17. Januzzi JL Jr, Butler J, Jarolim P, et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70:704-12.
18. Onishi T, Saha SK, Delgado-Montero A, et al. Global longitudinal strain and global circumferential strain by speckle-tracking echocardiography and feature-tracking cardiac magnetic resonance imaging: comparison with left ventricular ejection fraction. J Am Soc Echocardiogr. 2015;28:587-96.
19. Marwick TH, Leano RL, Brown J, et al. Myocardial strain measurement with 2-dimensional speckle-tracking echocardiography: definition of normal range. JACC Cardiovasc Imaging. 2009;2:80-4.
20. Kosmala W, Jellis CL, Marwick TH. Exercise limitation associated with asymptomatic left ventricular impairment: analogy with stage B heart failure. J Am Coll Cardiol. 2015;65:257-66.
21. Verma S, Garg A, Yan AT, et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care. 2016;39:e212-3.
22. Abduch MCD, Alencar AM, Mathias W, Vieira MLD. Cardiac mechanics evaluated by speckle tracking echocardiography. Arq Bras Cardiol. 2014;102:403-12.
23. Zhang X, Wei X, Liang Y, Liu M, Li C, Tang H. Differential changes of left ventricular myocardial deformation in diabetic patients with controlled and uncontrolled blood glucose: a three-dimensional speckle-tracking echocardiography-based study. J Am Soc Echocardiogr. 2013;26:499-506.
24. Ng AC, Sitges M, Pham PN, et al. Incremental value of 2-dimensional speckle tracking strain imaging to wall motion analysis for detection of coronary artery disease in patients undergoing dobutamine stress echocardiography. Am Heart J. 2009;158:836-44.
25. Enomoto M, Ishizu T, Seo Y, et al. Subendocardial systolic dysfunction in asymptomatic normotensive diabetic patients. Circ J. 2015;79:1749-55.
26. Holland DJ, Marwick TH, Haluska BA, et al. Subclinical LV dysfunction and 10-year outcomes in type 2 diabetes mellitus. Heart. 2015;101:1061-6.
27. Maeder MT, Karapanagiotidis S, Dewar EM, Kaye DM. Accuracy of echocardiographic cardiac index assessment in subjects with preserved left ventricular ejection fraction. Echocardiography. 2015;32:1628-38.
28. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358:2148-59.
29. Vergaro G, Emdin M, Iervasi A, et al. Prognostic value of plasma renin activity in heart failure. Am J Cardiol. 2011;108:246-51.
30. Lichtenbelt WDV, Westerterp KR, Wouters L. Deuterium dilution as a method for determining total-body water-effect of test protocol and sampling time. Brit J Nutr. 1994;72:491-7.
31. Schoeller DA, van Santen E, Peterson DW, Dietz W, Jaspan J, Klein PD. Total body water measurement in humans with 18O and 2H labeled water. Am J Clin Nutr. 1980;33:2686-93.
32. Khaled MA, Lukaski HC, Watkins CL. Determination of total body water by deuterium NMR. Am J Clin Nutr. 1987;45:1-6.
33. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-68.
34. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis. 2005;46:610-20.
35. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101:498-503.
36. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995;92:286-9.
37. Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, Dohi Y. Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail. 2005;11:504-9.
38. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179-86.
39. Anand IS, Latini R, Florea VG, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428-34.
40. Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction-the Framingham Heart Study. Circulation. 2003;107:1486-91.
41. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens. 2005;14:33-7.
42. Anker SD. Inflammatory mediators in chronic heart failure: an overview. Heart. 2004;90:464-70.
43. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-602.
44. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol. 2005;20:201-10.
45. Kameda K, Matsunaga T, Abe N, et al. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J. 2003;24:2180-5.
46. Tang WH, Brennan ML, Philip K, et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol. 2006;98:796-9.
47. Cicoira M, Rossi A, Bonapace S, et al. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J Card Fail. 2004;10:403-11.
48. Ernande L, Bergerot C, Rietzschel ER, et al. Diastolic dysfunction in patients with type 2 diabetes mellitus: is it really the first marker of diabetic cardiomyopathy? J Am Soc Echocardiogr. 2011;24(1268-1275):e1261.
49. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-72.
50. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-62.
51. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-74.
52. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392-406.
53. Schlaich M, Elliott R, Rudnicka C, Matthews V (2016) Os 33-04 regulation of Sglt-2 by the sympathetic nervous system. J Hypertens 34 Suppl 1-ISH 2016 Abstract Book: e394.
54. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol. 2014;13:28.
55. Zimlichman R. Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening. Curr Hypertens Rep. 2014;16:479.
56. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG outcome study? A unifying hypothesis. Diabetes Care. 2016;39:1115-22.
57. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy transduction. FASEB J. 1995;9:651-8.
58. Kohlhaas M, Liu T, Knopp A, et al. Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation. 2010;121:1606-13.
59. Baartscheer A, Schumacher CA, Wust RC, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60:568-73.
60. Baartscheer A, Hardziyenka M, Schumacher CA, et al. Chronic inhibition of the Na(+)/H(+)-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Brit J Pharmacol. 2008;154:1266-75.
61. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metab Clin Exp. 2004;53:159-64.
62. Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.
63. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab. 2013;17:695-708.
64. Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66:975-87.
65. Gallo LA, Ward MS, Fotheringham AK, et al. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Sci Rep. 2016;6:26428.
66. Singh JS, Fathi A, Vickneson K, et al. Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016;15:97.
67. Yamada H, Tanaka A, Kusunose K, et al. Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc Diabetol. 2017;16:63.